Status:
RECRUITING
Tumor Antigen Discovery for Innovative Cancer Immunotherapies in HCC: from Benchside to Bedside (HepAnt)
Lead Sponsor:
National Cancer Institute, Naples
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-100 years
Brief Summary
Tumor Antigen Discovery for Innovative Cancer Immunotherapies in HCC: From Benchside to Bedside (HepAnt) - Study of the Role of the Metagenome in Head and Neck Tumors Using Omics Techniques (HeNomics)...
Detailed Description
The aim of this study is to: * Analyze and compare the microbiota and the intestinal, salivary and intratumoral microbiome in patients with HCC, patients diagnosed with oncological pathology and in h...
Eligibility Criteria
Inclusion
- Histological diagnosis of primary HCC and other oncological pathology (Pascale Institute) or diagnosis of oncological pathology (without any exclusions) from an accredited medical-clinical facility (Fortore Mountain Community).
- Age ≥18 years
- Ability to give signed informed consent that includes compliance with the requirements and constraints listed in the informed consent form (ICF) and in this protocol.
- In the case of paraffin-embedded samples obtained from the UOC of Pathological Anatomy and/or the Institute's Biological Bank, informed consent cannot be acquired, in accordance with the Provision of the Privacy Authority containing the requirements relating to the processing of special categories of data, pursuant to art. 21, paragraph 1 of Legislative Decree 10 August 2018, no. 101, published in the Official Journal - general series - no. 176 of 29/07/2019, point 5 "Provisions relating to the processing of personal data carried out for scientific research purposes (gen. aut. n. 9/2016)" HEALTHY SUBJECTS
- clinical history free from diagnosis of tumor or neoplastic pathology treated during life
- Age ≥80 years
- Ability to give signed informed consent that includes compliance with the requirements and constraints listed in the informed consent form (ICF) and in this protocol
Exclusion
- Current pathologies requiring antibiotic therapy
- Diagnosis of pre-tumor pathology (in healthy subjects)
Key Trial Info
Start Date :
January 2 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2025
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06905262
Start Date
January 2 2023
End Date
September 30 2025
Last Update
April 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Istituto Nazionale Tumori di Napoli - IRCCS - Fondazione G. Pascale
Napoli, Italy, 80131